Tag: Bone density loss

Depo-Provera's use is associated with significant loss of bone mineral density (BMD), a concern that led the FDA to issue its strongest 'black box' warning. Understanding **what are the dangers of Depo-Provera** is crucial for anyone considering this contraceptive method.

While tenofovir is a highly effective antiviral drug, its different formulations have distinct safety profiles. A key question for patients and clinicians is which of the following side effects is common with tenofovir, particularly when comparing the older tenofovir disoproxil fumarate (TDF) and the newer tenofovir alafenamide (TAF). The answer depends heavily on the specific formulation and individual patient factors.

Depo-Provera, the injectable contraceptive, has not been officially discontinued or recalled by the U.S. Food and Drug Administration (FDA). Despite rumors suggesting otherwise, the product remains available by prescription, though it is at the center of growing lawsuits and regulatory warnings that explain why people ask, 'Why was Depo-Provera discontinued?'.

Over 10,000 HIV-positive individuals on tenofovir disoproxil fumarate (TDF) showed an increased risk for chronic kidney disease. This highlights that a major side effect of tenofovir, particularly the older TDF formulation, is renal and bone toxicity, which necessitates careful monitoring and management by healthcare professionals.

Anastrozole is a widely used and effective treatment for hormone-receptor-positive breast cancer in postmenopausal women. However, this medication comes with significant, and often long-term, adverse effects that patients must consider. Understanding **what is the dark side of anastrozole** is crucial for weighing the treatment's benefits against its substantial drawbacks.